Intranasal drug delivery isn't just for stuffy noses. Multiple drugs delivered through the nose have been approved in the past year despite not treating diseases of the nose.
The nonprofit Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) was established three years ago as a partnership between Takeda Pharmaceuticals Ltd. and three New York-based academic institutions – Memorial Sloan Kettering, The Rockefeller University and Weill Cornell Medical College – to translate potential targets into pharmaceutical candidates.
Esbriet (pirfenidone, Roche Holding AG) and Ofev (nintedanib, Boehringer Ingelheim GmbH) were approved to treat idiopathic pulmonary fibrosis (IPF) by the FDA two years ago – serendipitously on the same day – giving patients in the U.S. their first treatment options for the lung disease.
Marijuana has been used as a medical treatment for centuries. But there’s only one cannabinoid-based drug on the market, Marinol (dronabinol, Abbvie Inc.), which was approved back in 1985.
Investments in U.S. private biopharmaceutical companies tracked by BioWorld were up about 20 percent year over year in the third quarter, raising nearly $1.7 billion compared to about $1.4 billion in the year-ago quarter.
A new report from health communications company Ogilvy Healthworld released last week revealed a high level of social media activity by the top 20 pharmaceutical companies, but argues that pharma's social media strategy could use some tweaking.
In drama that could only be rivaled by a telenovela, last week the FDA approved Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy (DMD) drug, eteplirsen, branded Exondys 51.
In drama that could only be rivaled by a telenovela, last week the FDA approved Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy (DMD) drug, eteplirsen, branded Exondys 51.
At a workshop sponsored by the Duke-Margolis Center for Health Policy last week, representatives from the FDA, academia, industry and patient groups sat down to discuss the potential use of minimum residual disease (MRD) as a surrogate endpoint for hematologic malignancies.
